Samsung Heavy Industries Co. has received orders worth 266 billion won to build a liquefied natural gas (LNG) carrier and an S-Max oil tanker.
The order for a 206 billion-won LNG carrier, slated to be delivered by July 2023, was from an Oceanian company.
The S-Maxs are 125,000 to 200,000-ton oil tankers that can pass through the Suez Canal with a full cargo.
Samsung Heavy bagged a total of 2.9 billion won in orders in November.
Last week, it inked a $2.5 billion deal with a European company to provide ship blocks and other equipment.
In mid-November, Samsung Heavy received a 195 billion-won order from Oceania to build three S-Max oil tankers set for delivery by January 2023.
The company has an annual order target of $8.4 billion.


Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth
Nvidia Invests $1 Billion in Naver as South Korea AI Data Center Expansion Gains Momentum
ASML, Applied Materials Slide as China DUV Chip Equipment Breakthrough Sparks Market Jitters
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth
Tech Stock Positioning Nears Neutral as Investor Rotation Enters Final Phase, Deutsche Bank Says
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 



